Lyell Immunopharma, Inc. Earnings Per Share (Diluted)
Lyell Immunopharma, Inc. (LYEL) reported Earnings Per Share (Diluted) of -$1.92 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- Lyell Immunopharma, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.92.
- Lyell Immunopharma, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$1.10.
- Lyell Immunopharma, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$6.86.
- Lyell Immunopharma, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$2.13.
- Lyell Immunopharma, Inc. earnings per share, diluted for fiscal 2025 was -$16.06.
- Lyell Immunopharma, Inc. earnings per share, diluted for fiscal 2024 was -$26.23.
- Lyell Immunopharma, Inc. earnings per share, diluted for fiscal 2023 was -$18.70.
- Lyell Immunopharma, Inc. earnings per share, diluted for fiscal 2022 was -$0.74.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.92 10-Q · filed 2026-08-06 | -$3.05 10-Q · filed 2026-08-06 | -$9.56 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$11.83 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2026-03-31 | -$1.10 10-Q · filed 2026-05-06 | -$7.78 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$10.08 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$13.06 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-12-31 | -$6.86 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$9.26 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$12.44 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$16.06 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$2.13 10-Q · filed 2025-11-12 | -$4.93 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$8.38 10-Q · filed 2025-11-12 | -$21.07 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-06-30 | -$2.89 10-Q · filed 2026-08-06 | -$6.42 10-Q · filed 2026-08-06 | -$19.76 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$23.52 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-03-31 | -$3.54 10-Q · filed 2026-05-06 | -$0.18 10-Q · filed 2025-05-13 | -$16.98 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$20.84 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$24.63 derived: net income ÷ weighted average shares · filed 2026-05-06 | |||
| 2024-12-31 | -$13.71 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$17.64 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$21.40 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$26.23 10-K · filed 2026-03-12 | -$1.31 10-K · filed 2025-03-11 | |||
| 2024-09-30 | -$3.48 10-Q · filed 2025-11-12 | -$0.17 10-Q · filed 2024-11-07 | -$7.07 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$11.83 10-Q · filed 2025-11-12 | -$0.59 10-Q · filed 2024-11-07 | $1.94 derived: net income ÷ weighted average shares · filed 2026-04-24 | ||
| 2024-06-30 | -$3.59 10-Q · filed 2025-08-12 | -$0.18 10-Q · filed 2024-08-07 | -$8.36 10-Q · filed 2025-08-12 | -$0.42 10-Q · filed 2024-08-07 | $1.10 derived: net income ÷ weighted average shares · filed 2026-04-24 | $4.61 derived: net income ÷ weighted average shares · filed 2026-04-24 | ||
| 2024-03-31 | -$0.24 10-Q · filed 2025-05-13 | $0.51 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.53 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$16.66 derived: net income ÷ weighted average shares · filed 2026-04-24 | ||||
| 2023-12-31 | $0.08 derived: net income ÷ weighted average shares · filed 2026-04-24 | $0.46 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.52 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$18.70 10-K · filed 2026-03-12 | -$0.93 10-K · filed 2024-02-28 | |||
| 2023-09-30 | -$0.20 10-Q · filed 2024-11-07 | -$0.46 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$0.73 10-Q · filed 2024-11-07 | -$0.76 derived: net income ÷ weighted average shares · filed 2025-03-11 | ||||
| 2023-06-30 | -$0.26 10-Q · filed 2024-08-07 | -$0.52 10-Q · filed 2024-08-07 | -$0.56 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$0.84 derived: net income ÷ weighted average shares · filed 2025-03-11 | ||||
| 2023-03-31 | -$0.27 10-Q · filed 2024-05-06 | -$0.30 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$0.58 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$0.73 derived: net income ÷ weighted average shares · filed 2025-03-11 | ||||
| 2022-12-31 | -$0.03 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$0.32 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$0.46 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$0.74 10-K · filed 2025-03-11 | ||||
| 2022-09-30 | -$0.28 10-Q · filed 2023-11-07 | -$0.43 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$0.71 10-Q · filed 2023-11-07 | -$1.05 derived: net income ÷ weighted average shares · filed 2024-02-28 | ||||
| 2022-06-30 | -$0.15 10-Q · filed 2023-08-08 | -$0.43 10-Q · filed 2023-08-08 | -$0.77 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$0.98 derived: net income ÷ weighted average shares · filed 2024-02-28 | ||||
| 2022-03-31 | -$0.28 10-Q · filed 2023-05-04 | -$0.62 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$0.83 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$1.37 derived: net income ÷ weighted average shares · filed 2024-02-28 | ||||
| 2021-12-31 | -$0.35 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$0.55 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$1.12 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$1.84 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | -$0.20 10-Q · filed 2022-11-08 | -$0.79 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.66 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | -$1.47 10-Q · filed 2022-08-04 | -$3.91 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | -$3.19 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | -$15.69 10-K · filed 2023-02-28 | |||||||
| 2019-12-31 | -$24.04 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |